Physician profile
Mark Gilbert
NPI 1851534960
$1,687.99
in general payments reported to CMS, 2019-2025
11 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2021: $286 · 2022: $20.03 · 2023: $339 · 2024: $461 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $373.73 | 2019-2025 | Olympus, Rhino-Laryngo Fiberscope, Rhino-Laryngo Videoscope |
| Musculoskeletal Transplant Foundation INC. | $324.75 | 2025 | |
| Stryker Corporation | $234.18 | 2019-2024 | Scopis Ent, Na, Smartlock |
| Astrazeneca Pharmaceuticals Lp | $209.94 | 2021-2024 | Fasenra |
| Teleflex LLC | $163.79 | 2019-2024 | Pilling |
| Phathom Pharmaceuticals, INC. | $126.52 | 2024 | Voquezna |
| Davol INC. | $117.44 | 2021 | |
| Agiliti Surgical, INC. | $71.09 | 2021-2022 | |
| Pentax of America, INC. | $27.38 | 2023 | Pentax of America |
| Karl Storz Endoscopy-America | $23.34 | 2021 | |
| Galderma Laboratories, L.P. | $15.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.